FDA Seeks OK for Flu Virus Testing Reagent Info Collection
Published Date: 8/22/2025
Notice
Summary
The FDA is asking for approval to collect info about special test materials used to spot new types of flu viruses. This affects labs and health folks who track flu outbreaks, helping them stay ahead of the game. No big costs or delays are expected, but timely feedback is key to keep things moving smoothly.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA collecting flu reagent information
If you work in a laboratory or a public health agency, the FDA asked the Office of Management and Budget for permission to collect information about special test materials (reagents) used to detect specific novel influenza A viruses. This collection is meant to help labs and health officials find and track new flu strains more quickly. The agency says no big costs or delays are expected, but timely feedback is important to keep things moving.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12933 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!
2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12959 — Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.
2026-12953 — Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that RECTIV (nitroglycerin) ointment, 0.4%, wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules, so patients and pharmacies won’t face shortages or price spikes. If you’re a drug maker or user, this is good news for steady access and affordable options.
Previous / Next Documents
Previous: 2025-16064 — Agency Information Collection Activities; Proposed Collection; Comment Request; Animal Food and Egg Regulatory Program Standards
The FDA wants your thoughts on updating how they collect info about animal food and egg safety programs. If you’re involved in making or handling animal food or eggs, these changes could affect you. You’ve got 60 days to share your ideas before the new rules take shape—no extra costs yet, just a chance to help shape the future!
Next: 2025-16066 — Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational Device Exemptions Reports and Records
The FDA wants your thoughts on how it collects info about testing new medical devices before they hit the market. This affects companies and researchers who test these devices, and the FDA is asking for feedback over the next 60 days to keep things clear and efficient. No big money changes yet, just a chance to help shape the rules!